VolitionRx Supports Key Veterinary Symposium
HENDERSON, Nev. — VolitionRx Limited (NYSE AMERICAN: VNRX), a global leader in epigenetics, is proud to announce its sponsorship of an important industry symposium at the Veterinary Meeting and Expo (VMX), the largest veterinary education conference. This event takes place in a bustling Florida location, where veterinary professionals from around the world gather to share knowledge and advance their practice.
The renowned veterinarian, Dr. Sue Ettinger, will take center stage to present the insightful session titled "Utilizing the Nu.Q® Vet Cancer Test in Practice" on a designated day during the symposium. Dr. Ettinger, who is widely recognized as "Dr Sue Cancer Vet," brings invaluable expertise in veterinary oncology, making her presentation a highlight for attendees keen on exploring innovative diagnostic solutions.
Advantages of Early Cancer Detection in Pets
As cancer detection becomes increasingly refined, veterinarians can now utilize tools like the Nu.Q® Canine Cancer Test during routine checkups or comprehensive wellness exams for senior pets. These proactive measures are essential as they can lead to earlier diagnosis, which is crucial for effective treatment planning. By leveraging such advanced testing methods, veterinarians provide monitoring that empowers pet owners to make informed and timely decisions regarding their companions' health.
Dr. Tom Butera, the Chief Executive Officer of Volition Veterinary Diagnostics Development LLC, expressed enthusiasm about participating in this pivotal event. “We look forward to VMX 2026, where Dr. Ettinger will share her insights with regard to our Nu.Q® Vet Cancer Test. This event, drawing around 20,000 veterinary professionals, is a remarkable opportunity to showcase our innovative diagnostics alongside our dedicated partners.”
Explore the Future of Veterinary Diagnostics
At the Volition Veterinary Diagnostics Development booth, which will be listed as booth 2243, participants will be able to learn more about the groundbreaking Nu.Q® Test. This initiative is part of Volition's commitment to transforming veterinary care through cutting-edge technology and research.
VolitionRx is relentlessly focused on advancing the science of epigenetics, aimed at improving outcomes for both humans and animals through early disease detection and monitoring key health metrics. The company is committed to ensuring that life-altering diseases are detected sooner, allowing for better treatment options and lifestyle quality for affected patients.
Volition’s Continuing Mission
Through a series of dedicated research and development initiatives, Volition is rapidly commercializing effective, affordable blood tests. These tests target a variety of diseases, including certain cancers and NETosis-associated conditions, like sepsis. This approach emphasizes that early detection and monitoring do not just extend life—they can significantly enhance quality of life for patients.
Centered in Belgium, Volition also maintains an innovation laboratory in the U.S. and an office in London, showcasing its commitment to global health advancements. As VolitionRx pushes forward in creating significant breakthroughs in veterinary diagnostic history, their impact on the field continues to grow stronger.
Media Inquiries and Community Engagement
For those interested in further information about Volition's initiatives or the symposium itself, the media contact is Louise Batchelor. Although specific email addresses cannot be shared, inquiries can be directed to her contact number, which is publicly available.
Frequently Asked Questions
What is VolitionRx's primary focus?
VolitionRx focuses on advancing epigenetics, particularly in developing innovative diagnostic tests for early disease detection and monitoring.
When is the VMX symposium taking place?
The VMX symposium occurs at a premier veterinary conference, gathering thousands of professionals in the field.
What is the Nu.Q® Vet Cancer Test?
The Nu.Q® Vet Cancer Test is an innovative blood test designed to help detect cancer in dogs, facilitating early diagnosis and treatment.
How does early detection benefit pet health?
Early detection allows for timely intervention, increasing the chances of successful treatment and improving the quality of life for pets.
How can veterinarians incorporate the Nu.Q® test into practice?
Veterinarians can use the Nu.Q® test during annual checkups or senior wellness exams to monitor pets and detect potential health issues earlier.
